Management of severe acute to fulminant hepatitis B: To treat or not to treat or when to treat?

Liver International

Volumn 32, Issue 4, 2012, Pages 544-553

  Tillmann, Hans L ^a   Zachou, Kalliopi ^b   Dalekos, George N ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF THESSALY   (Greece)

Author keywords

Antivirals; Entecavir; Fulminant hepatitis B; Lamivudine; Liver transplantation; Tenofovir

Indexed keywords

ACETYLCYSTEINE; ADEFOVIR; BILIRUBIN; CATECHIN; ENTECAVIR; INTERFERON; LAMIVUDINE; TENOFOVIR; THYMOSIN; URSODEOXYCHOLIC ACID;

ANTIVIRAL THERAPY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG TREATMENT FAILURE; HEPATITIS B; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ADENINE; ANTIVIRAL AGENTS; GUANINE; HEPATITIS B; HUMANS; INTERFERONS; LAMIVUDINE; LIVER FAILURE, ACUTE; PHOSPHONIC ACIDS;

EID: 84858288892     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02682.x     Document Type: Review

References (106)

1. Wright R. Type B hepatitis: progression to chronic hepatitis. Clin Gastroenterol 1980; 9: 97-115.
2. Centers for Disease Control and Prevention (CDC). Incidence of acute hepatitis B-United States, 1990-2002. MMWR Morb Mortal Wkly Rep 2004; 52: 1252-4.
3. Barclay ST, Cameron S, Mills PR, et al. The changing face of hepatitis B in greater Glasgow: epidemiological trends 1993-2007. Scott Med J 2010; 55: 4-7.
4. Liew F, Ang LW, Cutter J, James L, Goh KT. Evaluation on the effectiveness of the national childhood immunization program in Singapore, 1982-2007. Ann Acad Med Singapore 2010; 39: 532-10.
5. Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27: 6550-7.
6. Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe - A review. Euro Surveill 2008; 13: pii: 18880.
7. Virus hepatitis B, C und D im Jahr 2009 in Deutschland. Robert Koch-Institut, Epidemiologisches Bulletin 2010; 20: 178-90.
8. Sako A, Yasunaga H, Horiguchi H, et al. Acute hepatitis B in Japan: incidence, clinical practices and health policy. Hepatol Res 2011; 41: 39-45.
9. Arteaga-Rodríguez A, Carrasco-Garrido P, Lopez de Andres A, et al. Trends of acute hepatitis B hospitalizations, comorbidities, fatality rate, and costs associated with the hospitalization in Spain (2001-2006). Eur J Gastroenterol Hepatol 2010; 22: 961-6.
10. Pyrsopoulos NT, Reddy KR. Hepatitis B. eMedicine, 2009; Available from: Accessed 6 August 2011.
11. Emekdas G, Cavuslu S, Oncul O, Artuk C, Armagan A. Trends of hepatitis B and C virus among blood donors over 16 years in Turkey. Eur J Epidemiol 2006; 21: 299-305.
12. Giusti G, Gaeta GB, Russo M, Bedarida G. HBsAg carries among blood donors in Italy - A multicenter study in 107 blood bank. Infection 1989; 17: 237-43.
13. Zervou EK, Dalekos GN, Boumba DS, Tsianos EV. Value of anti-HBc screening of blood donors for prevention of HBV infection: results of a 3-year prospective study in Northwestern Greece. Transfusion 2001; 41: 652-8.
14. Durro V, Qyra S. Trends in prevalence of hepatitis B virus infection among Albanian blood donors, 1999-2009. Virol J 2011 4; 8: 96.
15. Dalekos GN, Zervou E, Karabini F, Tsianos EV. Prevalence of viral markers among refugees from southern Albania: increased incidence of infection with hepatitis A, B and D viruses. Eur J Gastroenterol Hepatol 1995; 7: 553-8.
16. Ali M, Idrees M, Ali L, et al. Hepatitis B virus in Pakistan: a systematic review of prevalence, risk factors, awareness status and genotypes. Virol J 2011; 6: 8.
17. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
18. van Zonneveld M, van Nunen AB, Niesters HG, et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003; 10: 294-7.
19. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16: 94-103.
20. Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011; 55: 1215-21.
21. Jonas MM. Hepatitis B and pregnancy: an underestimated issue. Liver Int 2009; 29(Suppl 1): 133-9.
22. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151: 599-603.
23. Zhang HW, Yin JH, Li YT, et al. Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut 2008; 57: 1713-20.
24. Suzuki Y, Kobayashi M, Ikeda K, et al. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol 2005; 76: 33-9.
25. Möller B, Hopf U, Pöschke S, et al. Serological assessment of HBcAg and HBV DNA: its prognostic relevance in acute hepatitis B. Liver 1987; 7: 298-305.
26. Kuruüzüm Z, Ozgenç O, Havuk A, et al. Rate of chronicity and time of disappearance of HBsAg following acute hepatitis B. Hepatogastroenterology 2009; 56: 466-9.
27. Beasley RP, Hwang LY, Lin CC, Ko YC, Twu SJ. Incidence of hepatitis among students at a university in Taiwan. Am J Epidemiol 1983; 117: 213-22.
28. Seeff LB, Beebe GW, Hoofnagle JH, et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med 1987; 316: 965-70.
29. Tassopoulos NC, Papaevangelou GJ, Sjogren MH, et al. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987; 92: 1844-50.
30. Wang Z, Zhang J, Yang H, et al. Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol 2003; 71: 360-6.
31. Elefsiniotis IS, Glynou I, Magaziotou I, et al. HBeAg negative serological status and low viral replication levels characterize chronic hepatitis B virus-infected women at reproductive age in Greece: a one-year prospective single center study. World J Gastroenterol 2005; 11: 4879-82.
32. Hadziyannis SJ. Milestones and perspectives in viral hepatitis B. Liver Int 2011; 31(Suppl 1): 129-34.
33. Wai CT, Fontana RJ, Polson J, et al. Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat 2005; 12: 192-8.
34. Ozasa A, Tanaka Y, Orito E, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006; 44: 326-34.
35. Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J Hepatol 2008; 49: 625-33.
36. Wiegand J. Newly acquired hepatitis C-many hurdles from diagnosis until treatment initiation. J Gastroenterol Hepatol 2008; 23: 1782-4.
37. Kobayashi M, Arase Y, Ikeda K, et al. Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan. J Med Virol 2002; 68: 522-8.
38. Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13: 256-63.
39. Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int 2004; 24: 547-51.
40. Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45: 97-101.
41. Miyake Y, Iwasaki Y, Takaki A, et al. Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med 2008; 47: 1293-9.
42. Torii N, Hasegawa K, Ogawa M, Hashimo E, Hayashi N. Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B. Hepatol Res 2002; 24: 34.
43. Kondili LA, Osman H, Mutimer D. The use of lamivudine for patients with acute hepatitis B (a series of cases). J Viral Hepat 2004; 11: 427-31.
44. Hasan F, Owaid S, Ali M, et al. Lamivudine therapy for severe acute hepatitis B. J Hepatol 2005; 42(suppl.2): 178-9.
45. Lisotti A, Azzaroli F, Buonfiglioli F, et al. Lamivudine treatment for severe acute HBV hepatitis. Int J Med Sci 2008; 5: 309-12.
46. Delić D, Nesić Z, Prostran M, Boricić I, Svirtlih N. Treatment of subacute hepatitis B with lamivudine: a pilot study in Serbia. Vojnosanit Pregl 2009; 66: 199-202.
47. Roznovský L, Orságová I, Kloudová A, Mrázek J. Lamivudine therapy in patients with severe acute hepatitis B. Klin Mikrobiol Infekc Lek 2007; 13: 59-65.
48. Roussos A, Koilakou S, Kalafatas I, et al. Lamivudine treatment for acute severe hepatitis B: report of a case and review of the literature. Acta Gastroenterol Belg 2008; 71: 30-2.
49. Chalupa P, Holub M. Favorable outcome of severe acute hepatitis B in a patient treated with antithrombin III and antiviral therapy. Clin Infect Dis 2009; 49: 481.
50. Tsai SH, Chang HM, Hsieh CB, Chao YC, Hsieh TY. Acute fulminant hepatitis B in a patient with diabetic nephropathy treated successfully with concomitant lamivudine and molecular adsorbents recirculating system. J Infect 2006; 53: e19-23.
51. Yu JW, Sun LJ, Yan BZ, Kang P, Zhao YH. Lamivudine treatment is associated with improved survival in fulminant hepatitis B. Liver Int 2011; 31: 499-506.
52. Yu JW, Sun LJ, Zhao YH, Kang P, Li SC. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci 2010; 55: 755-83.
53. Scullard GH, Pollard RB, Smith JL, et al. Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. J Infect Dis 1981; 143: 772-83.
54. De Socio GV, Mercuri A, Di Candilo F, Baldelli F. Entecavir to treat severe acute hepatitis B. Scand J Infect Dis 2009; 41: 703-4.
55. Garfein RS, Bower WA, Loney CM, et al. Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatology 2004; 40: 865-73.
56. Igaki N, Nakaji M, Moriguchi R, et al. An outbreak of fulminant hepatitis B in immunocompromised hemodialysis patients. J Gastroenterol 2003; 38: 968-76.
57. Canbay A, Bechmann LP, Best J, et al. Crohn's disease-induced non-alcoholic fatty liver disease (NAFLD) sensitizes for severe acute hepatitis B infection and liver failure. Z Gastroenterol 2006; 44: 245-8.
58. Santos DC, Martinho JM, Pacheco-Moreira LF, et al. Fulminant hepatitis failure in adults and children from a Public Hospital in Rio de Janeiro, Brazil. Braz J Infect Dis 2009; 13: 323-9.
59. Kumagai I, Abe K, Oikawa T, et al. A male patient with severe acute hepatitis who was domestically infected with a genotype H hepatitis B virus in Iwate, Japan. J Gastroenterol 2007; 42: 168-75.
60. Michitaka K, Horiike N, Chen Y, et al. Infectious source factors affecting the severity of sexually transmitted acute hepatitis due to hepatitis B virus genotype C. Intervirology 2005; 48: 112-9.
61. Chattopadhyay S, Das BC, Hussain Z, Kar P. Hepatitis B virus genotypes in acute and fulminant hepatitis patients from north India using two different molecular genotyping approaches. Hepatol Res 2006; 35: 79-82.
62. Nagasaki F, Ueno Y, Niitsuma H, et al. Analysis of the entire nucleotide sequence of hepatitis B causing consecutive cases of fatal fulminant hepatitis in Miyagi Prefecture Japan. J Med Virol 2008; 80: 967-73.
63. Jochum C, Gieseler RK, Gawlista I, et al. Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion 2009; 80: 235-40.
64. Girke J, Wedemeyer H, Wiegand J, Manns MP, Tillmann HL. Acute hepatitis B: is antiviral therapy indicated? Two case reports. Dtsch Med Wochenschr 2008; 133: 1178-82.
65. Zachou K, Dalekos GN. Hepatitis B re-activation with rituximab therapy: treat the patient not the disease. Liver Int 2011; 31: 277-9.
66. Georgiadou SP, Dalekos GN. Which level of immunosuppression is harmful for occult hepatitis B virus infection? 'A million dollar' answer Liver Int 2009; 29: 1127-8.
67. Yazdany J, Calabrese L. Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines? Arthritis Care Res (Hoboken). 2010; 62: 585-9.
68. Sanchez MJ, Buti M, Homs M, et al. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol 2009; 51: 1091-6.
69. Brost S, Schnitzler P, Stremmel W, Eisenbach C. Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. World J Gastroenterol 2010; 16: 5447-51.
70. Stange MA, Tutarel O, Pischke S, et al. Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab. Z Gastroenterol 2010; 48: 258-63.
71. Rago A, Lichtner M, Mecarocci S, et al. Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen. Antivir Ther 2010; 15: 929-32.
72. Watanabe M, Shibuya A, Takada J, et al. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med 2010; 21: 333-7.
73. Christopeit M, Weber T, Abendroth J, et al. HBs seroconversion in a patient with acute hepatitis B treated with entecavir during immunosuppression against severe bronchiolitis obliterans in the course of chronic graft versus host disease. J Clin Virol 2010; 48: 218-9.
74. Uchiyama M, Tamai Y, Ikeda T. Entecavir as prophylaxis against hepatitis B virus reactivation following chemotherapy for lymphoma. Int J Infect Dis 2010; 14: e265-6.
75. Garg H, Sarin SK, Kumar M, et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011; 53: 774-80.
76. Holub M, Kořínková M, Chalupa P. Viral hepatitis B in a patient with follicular lymphoma treated with biological therapy. Klin Mikrobiol Infekc Lek 2011; 17: 30-2.
77. Romanet P, Vacher-Coponat H, Moal V, et al. Pitfall of hepatitis B surface antigen testing in a kidney transplant recipient presenting hepatitis B reactivation. Clin Res Hepatol Gastroenterol 2011; 35: 671-4.
78. Milazzo L, Corbellino M, Foschi A, et al. Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy. Transpl Infect Dis 2012; 14: 95-8.
79. Roche B, Samuel D. The difficulties of managing severe hepatitis B virus reactivation. Liver Int 2011; 31(Suppl 1): 104-10.
80. Wong VW, Wong GL, Yiu KK, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 2011; 54: 236-42.
81. Cohen SM, Levy RM, Jovanovich JF, Ahn J. Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B. J Clin Gastroenterol 2009; 43: 1008-10.
82. Kondo M, Kitada N, Kobayashi M, et al. A case of drug-induced liver injury caused by entecavir for treatment of hepatitis B virus reactivation during RCHOP in a patient with non-Hodgkin lymphoma. Gan To Kagaku Ryoho 2009; 36: 1199-201.
83. Thomas HC, Scully LJ, McDonald JA. Lymphoblastoid and recombinant alpha-A interferon therapy of chronic hepatitis B virus infection. The Royal Free Hospital experience. J Hepatol 1986; 3(Suppl 2): S193-7.
84. Levin S, Hahn T. Interferon system in acute viral hepatitis. Lancet 1982; 1: 592-4.
85. Milazzo F, Galli M, Fassio PG, et al. Attempted treatment of fulminant viral hepatitis with human fibroblast interferon. Infection 1985; 13: 130-3.
86. Sánchez-Tapias JM, Mas A, Costa J, et al. Recombinant alpha 2c-interferon therapy in fulminant viral hepatitis. J Hepatol 1987; 5: 205-10.
87. Kundu SS, Kundu AK, Pal NK. Interferon-alpha in the treatment of acute prolonged hepatitis B virus infection. J Assoc Physicians India 2000; 48: 671-3.
88. Tassopoulos NC, Koutelou MG, Polychronaki H, Paraloglou-Ioannides M, Hadziyannis SJ. Recombinant interferon-alpha therapy for acute hepatitis B: a randomized, double-blind, placebo-controlled trial. J Viral Hepat 1997; 4: 387-94.
89. Gorbarets IP, Ketiladze ES, Farber NA, Bugaeva NP, Braginskiǐ DM. [Reaferon treatment in acute HBsAG-positive viral hepatitis]. [Article in Russian] Klin Med (Mosk) 1990; 68: 65-8.
90. Seremba E, Sanders CM, Jain MK, et al. Use of Nucleoside Analogues in HBV Related Acute Liver Failure. Program No. 95. 2007 Abstract Viewer. Boston, Massachusetts: American Association for the Study of Liver Diseases.
91. Gimson AE, Tedder RS, White YS, Eddleston AL, Williams R. Serological markers in fulminant hepatitis B. Gut 1983; 24: 615-7.
92. Brechot C, Bernuau J, Thiers V, et al. Multiplication of hepatitis B virus in fulminant hepatitis B. Br Med J (Clin Res Ed) 1984; 288: 270-1.
93. Fong TL, Akriviadis EA, Govindarajan S, Valinluck B, Redeker AG. Serum hepatitis B viral DNA in acute viral hepatitis B. Ann Intern Med 1989; 110: 936-7.
94. Guidotti LG, Rochford R, Chung J, et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-9.
95. Murray JM, Wieland SF, Purcell RH, Chisari FV. Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci USA 2005; 102: 17780-5.
96. Whalley SA, Murray JM, Brown D, et al. Kinetics of acute hepatitis B virus infection in humans. J Exp Med 2001; 193: 847-54.
97. Galli M, Crocchiolo P, Negri C, et al. Attempt to treat acute type B hepatitis with an orally administered thymic extract (thymomodulin): preliminary results. Drugs Exp Clin Res 1985; 11: 665-9.
98. Galský J, Bansky G, Holubová T, Kõnig J. Effect of ursodeoxycholic acid in acute viral hepatitis. J Clin Gastroenterol 1999; 28: 249-53.
99. Fabris P, Tositti G, Mazzella G, et al. Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study. Aliment Pharmacol Ther 1999; 13: 1187-93.
100. Schomerus H, Wiedmann KH, Dölle W, et al. (+)-Cyanidanol-3 in the treatment of acute viral hepatitis: a randomized controlled trial. Hepatology 1984; 4: 331-5.
101. (+)-cyanidanol-3 (no authors listed). Lancet 1982; 1: 549.
102. Weiss L, Hildt E, Hofschneider PH. Anti-hepatitis B virus activity of N-acetyl-L-cysteine (NAC): new aspects of a well-established drug. Antiviral Res 1996; 32: 43-53.
103. Stravitz RT, Kramer DJ. Medscape. Management of acute liver failure. Nat Rev Gastroenterol Hepatol 2009; 6: 542-53.
104. Gunduz H, Karabay O, Tamer A, et al. N-acetyl cysteine therapy in acute viral hepatitis. World J Gastroenterol 2003; 9: 2698-700.
105. Thompson ND, Perz JF. Eliminating the blood: ongoing outbreaks of hepatitis B virus infection and the need for innovative glucose monitoring technologies. J Diabetes Sci Technol 2009; 3: 283-8.
106. U.S. Public Health Service. Updated U.S. Public health service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2001; 50: 1-52.